Join our mailing list to receive the latest updates and alerts Flag Subscribe

Fredrikson & Byron acted as legal counsel to Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, in its acquisition of Asuragen Inc., a leader in the development, manufacturing and commercialization of genetic carrier screening and oncology testing kits for initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones. Bio-Techne anticipates the acquisition to close in the fourth quarter of its fiscal 2021.

Fredrikson’s legal team included Ryan Brauer, Zach Olson, Aleida Conners and Tash Van Lieshout.

Read the news release.

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.